Centessa Pharmaceuticals
Centessa's CMC group is seeking a Senior Director of Analytical Development within the CMC group. The successful candidate will have hands-on experience in the development and validation of raw material, in-process, small molecule drug substance, and solid oral dose drug product methods at all stages of development. Reporting to the VP, CMC, the Senior Director will drive analytical method gap assessments, method development, and strategy at various CDMOs and liaise cross-functionally with drug substance and drug product teams across programs.
Centessa Pharmaceuticals is a global biopharmaceutical company that uses an asset‑centric, portfolio model to accelerate the development of innovative medicines. With a patient‑centric mission, Centessa advances programs across sleep‑wake, neurological, neurodegenerative and psychiatric disorders — notably pursuing an Orexin Receptor 2 agonist program. The company combines specialized operating subsidiaries and centralized capabilities to move preclinical and clinical‑stage assets efficiently toward regulatory approval and commercialization. Centessa partners with academic and industry collaborators to translate promising science into transformative treatment options for patients.
Why Centessa Pharmaceuticals (CNTA) Is Up 5.7% After Advancing ORX750 Toward Registrational Sleep-Disorder Trials
1 day ago
FMR LLC's Strategic Acquisition of Centessa Pharmaceuticals Shar
1 month ago
Centessa Pharmaceuticals plc Announces Underwritten Public Offering of American Depositary Shares
Nov 11, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Centessa Pharmaceuticals.
80% above the average for this role
Centessa (NASDAQ: CNTA) commences underwritten ADS offering; 30-day option up to 15%
Nov 11, 2025
Associate Director, CMC Analytical Development – Small Molecule
Beeline Medicines
Senior Scientist, Analytical Development and Quality Control (Drug Product)
Nurix
Director, CMC Drug Substance
Olema Oncology
Director, CMC Analytical Development – Biologics
Beeline Medicines
Director, Analytical Development (Small Molecule)
Structure Therapeutics
Technical Lead
Sobi